A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina

Last updated: July 4, 2025
Sponsor: Takeda
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cytomegalovirus Infections

Treatment

No Intervention

Clinical Study ID

NCT06213974
TAK-620-4008
  • Ages > 12
  • All Genders

Study Summary

The main aim of this study is to learn about the safety of Maribavir in adults and children with post-transplant CMV infection in routine clinical practice in Argentina.

The other aim is to study the effectiveness of the treatment with Maribavir in routine clinical practice in Argentina.

Participants will be treated by their doctors according to normal medical practice. Study data will be collected either from information already available in the medical records or during study conduct.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult participants (18 years or older) and pediatric participants (12 years of age and older and weighing at least 35 kilogram [kg]) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet in the real-world setting of common clinical practice in Argentina.

  • Have received at least one dose of maribavir according to approved indications.

  • Have signed the mandatory informed consent/assent that has been agreed with national regulatory authorities (ANMAT) as applicable.

Exclusion Criteria

  • There are no specific exclusion criteria.

Study Design

Total Participants: 10
Treatment Group(s): 1
Primary Treatment: No Intervention
Phase:
Study Start date:
September 03, 2024
Estimated Completion Date:
September 01, 2026

Connect with a study center

  • IC Projects

    City of Buenos Aires, C11119ACN
    Argentina

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.